Insmed said it is discontinuing work on Brinsupri in a form of chronic rhinosinusitis after the inflammation drug failed a Phase 2b study. The Bridgewater,
What a year! The XBI is up, M&A is bumping and the vibes are improving. But it ain’t all Christmas cookies. As has become our
Early returns suggest that Takeda’s $4 billion immunology bet appears to be paying off. Takeda said Thursday that its drug zasocitinib succeeded in two Phase
Plus, news on: Orum, FoRx, Gain Therapuetics and Antigenix: 💉 FDA approves injected version of Rybrevant: US regulators cleared a subcutaneous version of the Johnson
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Alnylam Pharmaceuticals is spending $250 million
Insilico Medicine is steps away from an initial public offering on the Hong Kong Stock Exchange after stalling on a few prior attempts.
Insilico is seeking to raise net proceeds of approximately …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844